98% of Bruce G.'s position are options. NO RISK.
Henry Grausz, M.D...................................... 5,817,993(2) 23.7%
1001 G. Street, N.W.
Suite 200 East
Washington, D.C. 20001
Isidore S. Edelman, M.D. .............................. 2,411,681(3) 9.9
464 Riverside Drive, # 61
New York, NY 10027
Pasteur Merieux Serums & Vaccins, S.A. ................ 2,000,000(4) 8.0
58 Avenue Leclerc
69007 Lyon, France
Bruce C. Galton(1)..................................... 1,411,157(5) 5.5
Franklin J. Iris(1).................................... --(6) *
Thomas P. Carney, Ph.D.(1)............................. 150,000(7) *
Frank G. Stout(1)...................................... 600(8) *
Richard S. Dondero..................................... 447,207(9) 1.8
Robert S. Naismith, Ph.D.(1) .......................... 400,000(10) 1.6
All directors and executive officers
as a group (6 persons)................................ 2,408,964(11) 9.0
</TABLE>
- ----------
* less than 1%
2
<PAGE>
(1) c/o Cistron Biotechnology, Inc. ,10 Bloomfield Avenue, Pine Brook, New
Jersey 07058.
(2) Includes 259,587 shares issuable upon currently exercisable options.
(3) Includes 54,374 shares issuable upon currently exercisable options, but
does not include 194,935 shares owned by Dr. Edelman's spouse, as to which
he disclaims beneficial ownership.
(4) Includes 1,333,333 shares of the Company's Common Stock and a currently
exercisable warrant to purchase 666,667 shares of the Company's Common
Stock. See "Certain Relationships and Related Transactions."
(5) Includes 1,365,960 shares issuable upon exercise of currently exercisable
options.
(6) No shares or options owned as of the Record Date.
(7) Consists of 150,000 shares issuable upon exercise of currently exercisable
options.
(8) Mr. Stout disclaims beneficial ownership of 302,289 shares and 136,870
shares owned by the New England Medical Center Hospitals, Inc. and
Wellesley College, respectively, the Institutions of which Mr. Stout
serves as designee on the Company's board of directors.
(9) Includes 431,722 shares issuable upon exercise of currently exercisable
options.
(10) Consists of a currently exercisable warrant (the "Naismith Warrant") to
purchase 400,000 shares of the Company's Common Stock. The Naismith
Warrant was originally issued by the Company to BlueStone Capital
Partners, LP ("BlueStone") in October 1998. |
